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ABSTRACT 
Alzheimer's disease (AD) is the most common type of dementia in the 
elderly. The deposit of extracellular amyloid B-peptide (AB) is a distinct feature of the 
disease. Recent studies have shown that AB interferes with glucose uptake in cultured 
neurons; however, how AB inhibits glucose uptake is not know. This study proposed a 
pathway in which A625-35. a neurotoxic portion of the AB peptide identical to the 25-35 
amino acid-sequence in AB, decreases neuronal glucose uptake. The inhibitory effect of 
A625-35 on neuronal glucose uptake was reduced by a G protein antagonist (GPAnt-2). In 
the first part of the study, we demonstrated a signaling pathway in which AB25-35, a 
neurotoxic portion of the AB peptide corresponding to amino acids 25-35, inhibits neuronal 
glucose uptake by hippocampal neurons. The GPAnt-2, which blocks Gs, prevented the 
inhibitory effect of AB on the glucose uptake. Cholera toxin, which stimulates adenylyl 
cyclase by activating Gs protein, also inhibited neuronal glucose uptake. Furthermore, the 
inhibitory effect of cholera toxin on glucose uptake was potentiated by .AB. Exposure of cells 
to AB resulted in a transitory increase in intracellular levels of cAMP. Addition of dibutyryl 
cAMP (BticAMP) or an adenylyl cyclase activator, forskolin, to the culture medium 
inhibited neuronal glucose uptake, and a protein kinase A inhibitor (KT-5720) blocked the 
AB-mediated inhibition of glucose uptake. Thus, our findings suggest that AB inhibits 
glucose uptake by activating the Gs-coupled receptors and involves the cAMP-PKA system. 
The second part of this study examined the effects of insulin and insulin-like growth factor I 
(IGF-I) on the inhibitory effect of AB on neuronal glucose uptake. Insulin and IGF-I elevated 
neuronal glucose uptake, but the effect of IGF-I was more potent than insulin. Neurons 
exposed to AB25-35 showed 38% less glucose uptake than the control. However, IGF-I and 
insulin prevented this inhibitory effect of AB. To study the signaling pathway of IGF-I that 
stimulates glucose uptake, hippocampal neurons were studied for their glucose uptake 
following exposure to a phosphoinositide 3-kinase (PI3K) inhibitor (LY294002) or a 
mitogen-activated protein kinase (MAPK) inhibitor (PD-98059). The LY294002 decreases the 
stimuiatory effect of IGF-I on neuronal glucose uptake while PD-98059 has no effect on the IGF-I 
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increase neuronal glucose uptake. The results demonstrates that (1) both IGF-I and insulin are 
effective in elevating neuronal glucose uptake and preventing the inhibitory effect of AB and 
(2) PI3K plays a regulatory role in neuronal glucose uptake. The present study shows that AB 
may inhibit neuronal glucose uptake via G protein and cAMP-dependent protein kinase 
pathway and insulin and IGF-I reverse the AB inhibition effect on neuronal glucose uptake. 
However, how the two hormones interact to the AB inhibition effect need to be further 
investigated. 
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CHAPTER 1, GENERAL INTRODUCTION 
Neurons in Alzheimer's disease 
Alzheimer's disease (AD) claims 65% of the dementias found in the elderly [70]. AD is 
characterized by deposition of amyloid B-peptide (A6) in many areas of the brain. This extra­
cellular peptide lies in the neuropathological lesion, the neuritic plaque. Neuritic plaques are 
classified into two types: a diffuse amyloid plaque which consists only of an amorphous form 
AB and a mature plaque, which consists of a core of aggregated amyloid filament surrounded 
by dystrophic neurites and reactive glial cells [87], A6 is derived from a transmembrane glyco­
protein called A6 precursor protein (BAPP) [45]. It is a 39 - 43 amino acid peptide cleaved from 
extracellular and transmembrane domains of BAPP [86]. 
The evidence supporting AB deposition as the primary pathological process is the iden­
tification of pathogenic mutations in the AB precursor protein gene and neuropathology similar 
to AD in transgenic mice overexpressing BAPP [27.42]. Although degenerating neurons in 
transgenic mice accompany the AB deposition, the mechanisms involved in A6-mediated neu­
ronal degeneration are not well understood, but it has been shown that the neurotoxic portion of 
AB is amino acids 25-35 (AB25-35) of the full-length A6 peptide [62,113]. In primary cell 
cultures, AB is neurotoxic [73,88,114]. This toxic effect seems to depend on the stage of neu­
ronal differentiation and the aggregation stage of AB [73,74,92]. Thus, AB was neurotoxic only 
to mature hippocampal neurons [114], But even neurons at the early stages undergo 
neurodegeneration if exposed to aggregated AB [73]. Although synthetic AB has been shown to 
have neuronal toxicity on cultured cells, injecting this synthetic peptide into the brain of young 
rats did not induce neuronal degeneration. In contrast, injection of AB (AB 1 -40) into old rats did 
result in neurodegeneration [52]. Similarly, in the brain of the aging rhesus monkey, AB caused 
neurodegeneration, while it did not in the brain of the young rhesus monkey [28], suggesting 
that AB-induced neuronal death is specific to aging. 
AB-mediated inhibition of neuronal glucose uptake 
In vitro study has shown that A6 impairs glucose uptake in hippocampal neurons [60] 
and astrocytes [69]; however, it is not known whether AB affects neuronal and astrocytic glu­
cose uptake in AD patients. There is some evidence suggesting that glucose metabolism is 
changed in the brains of AD patients [20.46.76.78]. Studies by positron emission tomography 
(PET) scans detected a decrease in glucose uptake in the cerebral cortex [20.46.76.78]. It was 
calculated that reduction of cerebral glucose utilization ranges from 19% in mild cases to 40% 
and more in severe cases of AD [41.54]. Immunohistochemical study further revealed a de­
crease in glucose transporters (GLUTI. GLUT3) in several brain regions, including the hippoc­
ampus, the area commonly affected in AD patients [36,93]. Reduced glucose uptake by indi­
viduals genetically at risk for developing AD also supports the notion that glucose deprivation 
precedes neuronal degeneration [49,72,77]. Although in vitro effect of AB may not accurately 
represent an in situ situation, previous in vitro experiments [2.61] have often proved their use­
fulness in simulating cellular responses in situ [29.30.32]. Thus, it is likely that the decreased 
cerebral glucose uptake in AD may reflect, in part, the inhibitory effect of AB on neuronal and 
astrocytic glucose uptake. 
In healthy, nonstarved mammalian brain, glucose is the only substrate for the formation 
of energy in the form of ATP [21]. Glucose deprivation results in increased use of endogenous 
substrates, depletion of ATP, membrane depolarization, extracellular accumulation of excita­
tory amino acids, loss of neuronal homeostasis and ultimately neuronal cell death [61]. Neurons 
interfered with glucose uptake or exposed to AB result in impaired mitochondrial activity and 
suppressed production of ATP [61]. Based on the rates of oxidized glucose and oxygen, it was 
estimated that the rate of cerebral ATP formation decreases by 7% in early-onset AD, and 20% 
in late-onset AD [39]. Such metabolic impairment of neurons was shown to increase their vul­
nerability to glutamate toxicity and oxidative insults [61]. It was shown that AB inhibits astro­
cytic glutamate uptake [69] and stimulates microglial release of toxic levels of nitric oxide [8]. 
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Thus, their functional changes by AS may be fatal to those neurons suffering from glucose 
deficiency. 
Regulation of neuronal glucose 
The mechanism involved in A6 inhibition of glucose uptake is not known. It was sug­
gested that lipid peroxidation by AB is involved in impairment of neuronal glucose transport 
[60]. Lipid peroxidation generates 4-hydroxynonenal (HNE). Since HNE binds to neuronal 
glucose transporter GLUTS and exogenous application of HNE induces an impairment of glu­
cose transport, it is suggested that HNE binding with GLUTS inhibits glucose transport in 
neurons. However, there is no direct evidence at present showing functional impairment of 
GLUTS by HNE binding. In spite of importance of glucose for neural functions, very little is 
known about the regulatory mechanisms involved in neuronal glucose uptake, GLUTS expres­
sion, and GLUT translocation from cytoplasmic pool to plasma membrane. In neurons, the rate 
of glucose uptake depends on the number of GLUTS on the plasma membrane, not on extracel­
lular glucose concentration [71]. In cultured hippocampal neurons, A6 did not affect GLUTS 
orotein levels, even after 6 hr of A6 treatment [60]. This suggests that AB induces an intrinsic 
ft-nctional change in GLUTS on the plasma membrane. In adipocytes, phosphorylation of GLUT4 
is known to inhibit insulin-stimulated glucose transport [47.57], Phosphorylation of GLUT4 is 
confined to the intracellular domain at the COOH-terminal region and this terminal region 
appears to play an important role in the regulation of transport activity [7S]. In Chinese hamster 
ovary (CHO) cells, changing Ser*®® to an Ala prevented phosphorylation of GLUT4: however, 
dibutyryl cAMP (Bt,cAMP) was still able to inhibit glucose transport even after this mutation 
[75]. Although the data seems to suggest that phosphorylation is not required for the inhibition 
of GLUT4, it is not conclusive. The effect of phosphorylation may also depend on the cell type 
in which the transporter is expressed. For example, the function of GLUT4 is to transport glu­
cose in response to insulin, a function not present in CHO cells [43,91 ]. It was also shown that. 
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in CHO ceils, cAMP-dependent PKA had no effect on glucose uptake [75]. Interestingly, PKA 
inhibitor, H-89, was shown to prevent A6-induced apoptotic cell death [99], It is, therefore, 
conceivable that phosphorylation of GLUT3 inhibits neuronal glucose uptake. A6 inhibition of 
neuronal glucose uptake could also be mediated by Ca^Vcalmodulin-sensitive adenylyl cyclase 
and increase cAMP levels, the process known to occur in the hippocampus [65], However, 
Ca-Vcalmodulin-mediated inhibition of glucose uptake is less likely because it was shown that 
AB-induced apoptosis was not inhibited by KN-62, an inhibitor of Ca-Vcalmodulin dependent 
protein kinase [98]. 
To date the role of cAMP in the regulation of neuronal glucose is not known. Forskolin 
was shown to stimulate adenylate cyclase, elevating the intracellular cAMP level and inhibiting 
the glucose uptake by neurons and astrocytes [34]. Dibutyryl cAMP was also shown to inhibit 
glucose uptake in L6 myoblast [58] and hamster ovary ceils [73]. In vitro study suggests that 
AB inhibits glucose uptake by activating the cAMP-PKA system. How these in vitro data relate 
to the decreased glucose metabolism in AD is not certain. It is possible that the decreased 
cerebral glucose uptake shown in AD may reflect, in part, the inhibitory effect of AB on neu­
ronal and astrocytic glucose uptake. Such an hypothesis infers the presence of functional G 
protein-stimulated activity of adenylyl cyclase and cAMP in AD patients. Postmortem studies 
of AD patients have shown normal G-protein levels [12,63,79,104], catalytic activity of cAMP, 
and PKA [7,24,64,81]. However, the regulatory function of G protein on adenylyl cyclase was 
reported as either normal [79] or reduced [12,24,84]. This inconsistency may reflect differ­
ences in postmortem instability of the enzyme at different stages of Alzheimer's disease [7]. 
The regulatory function of G protein on adenylyl cyclase could also be affected only at the 
terminal stage of AD disease. 
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Protective role of insulin and insulin-like growth factor (IGF) on A6 inhibition of neu­
ronal glucose uptake 
Neurons exposed to AB become more susceptible to glucose deprivation [11]; but, IGF-
I and IGF analogues are effective in promoting cell survival under such condition [10.35]. 
Furthermore, IGF-I is shown to protect, and more importantly, to rescue rat hippocampal neu­
rons against AB toxicity [18]. The protective mechanism of IGF-I is not known, but it was 
shown that insulin and IGF-I act as a neuronal growth factor [89.103]. In transgenic mice that 
overexpress IGF-I in the brain, glucose uptake increases significantly in the brain [31 ]. /n vitro 
studies have also shown that IGF-I increases glucose uptake in skeletal muscle, L6 myombes 
and PC12 cells [23.37.56.111], while insulin increases glucose uptake in PC 12 cells [III]. 
Although several studies in humans suggest the imponance of insulin in hippocampal energy 
metabolism [26.40] and memory facilitation [13.14], it is not known whether insulin and IGF-
I promote glucose uptake by neurons. In both skeletal muscle and adipocytes, insulin and IGF-
I were shown to stimulate translocation of GLUT4. increasing the number of GLUT4 in the 
plasma membrane [59.71,110]. Similarly, insulin and IGF-I were shown to translocate GLUT3 
in L6 myotubes [67]; however, what regulates translocation of neuronal GLUT3 is not known 
at present. 
Whether insulin can regulate glucose metabolism within the brain has been a contro­
versy for some time. An increasing body of evidence suggests that insulin has a vital role in 
brain function [108]. E.xpression of the insulin gene and insulin synthesis occur in a highly 
specific pattern, with the highest density in hippocampal pyramidal neurons [17]. Plasma insu­
lin was also shown to cross the blood-brain barrier by saturable receptor-mediated transcytosis, 
and residual insulin is removed through the CSF [3,5,85]. At present, normal insulin and IGF-
I levels in the human brain are not known. However, a deficit in these hormones is suspected in 
the brains of AD patients because of their higher plasma insulin and IGF-I, and lower CSF 
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insulin levels [15]. Insulin and IGF-I receptors are also present in the human brain [68.80,83], 
and their numbers increase in the brains of AD patients [6,16,25]. If this proliferation of insulin 
and IGF-I receptors is the brain's attempt to compensate for a lack of insulm and IGF-I, the 
reduced cerebral glucose utilization found in AD may reflect the cerebral insulin and IGF-I 
deficit in AD [41], IGF is synthesized primarily in the liver, but it is also made by neurons in the 
developing brain [4]. 
Alzheimer's patients have abnormally low blood glucose [44] and infusion of glucose 
has been shown to enhance memory in Alzheimer's patients and normal elderly adults [13,50], 
Because glucose infusion is usually associated with elevation of plasma insulin, a group of 
Alzheimer's patients was further assessed by raising plasma insulin, but preventing a rise in 
plasma glucose [14]. There was a striking memory enhancement in these patients, suggesting a 
functional importance of insulin in the brain. Insulin levels in CSF can be elevated by oral 
glucose load in patients with AD [26]. Furthermore, intraventricular administration of insulin 
exerts anabolic effects on hippocampal energy metabolism. In contrast, intraventricular injec­
tion of streptozotocin (STZ), the inhibitor of tyrosine kinase of the insulin receptor, caused 
significant decreases in glucose utilization and ATP levels [40]. At present, insulin levels in the 
human brain is not known; however, insulin deficit in the brains of Alzheimer's patients is 
suspected because of their higher plasma insulin and lower CSF insulin levels in Alzheimer's 
patients [15]. The proliferation of insulin and IGF-I receptors in AD [16,25] was interpreted as 
the brain's attempt to compensate for a lack of insulin and IGF-I. The insulin deficit in the brain 
may also be responsible for the reduced cerebral glucose utilization found in AD [41]. 
Insulin and IGF-I share structural and functional features, including an a-subunit that 
binds the hormone-like agent and a B-subunit that has a tyrosine-specific protein kinase [101], 
The metabolic effects of these hormones are initiated by their binding to the extracellular do­
main of the specific membrane receptors, which lead to the activation of, among others, Ras 
and phosphoinositide 3-kinase (PI3K) [33,90]. Many of these kinases appear to be arranged in 
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cascades, including a cascade that results in the elevation of glucose uptake in insulin sensitive 
cells [100]. The signaling pathways that stimulate neuronal glucose uptake are not known. In 
adipocytes, PI3K was shown to increase GLUT4 translocation to the plasma membrane and 
glucose transport [22,38,48.51]. Furthermore, PI3K inhibitor, LY294002, was shown to inhibit 
glucose uptake [82] by interfering with insulin mediated translocation of GLUT4 [9]. 
The short-term metabolic effect of insulin (e.g., increase in glucose transport) appears 
to require PI3K. In both skeletal muscle and adipocytes, insulin and IGF-I control the actual 
number of GLUT4 in the plasma membrane by stimulating translocation of GLUT4 from an 
intracellular store to the plasma membrane [59,71,110]. Similarly, insulin and IGF-I were shown 
to translocate GLUT3 in L6 myotubes [67]; however, what regulates translocation of neuronal 
GLUT3 is not known at present. In adipocytes, PI3K mediates the following events: (i) insulin-
induced reorganization of actin filaments [106], (ii) activation of 3-phosphoinositide-depen-
dent PKB [I] and PKC-zeta [94,95], (iii) GLUT4 translocation to the plasma membrane, (iv) 
glucose transporter exocytosis [112] and (v) glucose transport [22,38,48,51 ]. Very little is known 
about PKB and PKC-zeta in their role in glucose metabolism. Activation of PKB induces in­
crease in glucose uptake, glycogen synthesis, and protein synthesis in L6 myotubes. Such PKB 
action is independent ofRas and MAPK activation [19,55,100,102]. Insulin also activates PKC-
zeta through PI3K, contributing to the activation of GLUT4 translocation [94,95]. Thus, PKB 
and PKC-zeta appear to act as key enzymes for multiple biological functions of insulin, includ­
ing glucose uptake. PKB may also stimulate glucose uptake by phosphorylating GLUT3, much 
like PKB in adipocytes that phosphorylates phosphodiesterase 3B (PDE-3B) [109]. The MAPK 
cascade, on the other hand, may have a role in the regulation of gene transcription, and hence 
the more long-term effect of insulin [66]. Insulin and IGF-I activate RasGTP and MAPK cas­
cade in 3T3-LI adipocytes, skeletal muscle and myotubes [19,53,55,96,102,107]. Chronic (16 
hr) treatment with insulin was shown to increase GLUT3 mRNA and protein in UMR 106-01, 
a clonal osteosarcoma cell line [97], while, IGF-I induced p53 mRNA in cardiac muscle cells 
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[105], If insulin deficit occurs in the brain and such deficit accompanies deposition of Afi, it is 
conceivable that the long-term neuronal effect of such condition include significant reduction 
in numbers of GLUTS, and subsequent decrease in glucose uptake. 
Although there are numerous published reports linking A6 to neurotoxicity in vitro and 
in vivo, research investigating the mechanisms involved in reduced glucose utilization in AD 
has been primarily focused on free radicals generated by AC [61]. It has been shown by others 
that neurons exposed to A6 become more susceptible to glucose deprivation; but, IGF-I and 
IGF analogues are effective in promoting cell survival under such condition. Furthermore, IGF-
I is shown to protect and rescue rat hippocampal neurons against A6 toxicity. Studies in human 
also suggest the importance of insulin in hippocampal energy metabolism [26,40] and memory 
facilitation [13,14]. Reduced cerebral glucose uptake by individuals genetically at risk for de­
veloping AD also supports the notion that glucose deprivation precedes neuronal degeneration 
[49,72,77]. A perturbed control of glucose breakdown may severely damage cellular homeosta­
sis and subsequently causes not only a substantial impact on cellular function, but also in­
creased neuronal vulnerability to, among others, glutamate toxicity and oxidative insults. There­
fore, understanding the mechanisms involved in neuronal glucose regulation by AB and hor­
mones (insulin and IGF-I) are a critical importance for improving neuronal glucose utilization 
in AD. 
Research objectives 
There were two research objectives. The first objective was to test the hypothesis that G 
protein and cAMP mediate AB25-35 inhibition of neuronal glucose uptake. This part was car­
ried out by studying the effect of (1) G protein antagonist on glucose uptake, (2) cholera toxin 
on glucose uptzike, (3) A625-35 on intracellular cAMP, (4) cAMP on glucose uptake, and (5) a 
protein kinase A (PKA) inhibitor (KT-5720) on glucose uptake. The second objective was to 
test the hypothesis that insulin and IGF-1 prevent the inhibitory effect of A6 on neuronal glu­
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cose uptake by either PI3K or MAPK. This part was carried out by studying the effect of A625-
35 on neuronal glucose uptake under the influence of (I) insulin or IGF-I and (2) PI3K inhibi­
tor (LY294002) or mitogen-activated protein kinase (MAPK) inhibitor (PD-98059). 
Dissertation organization 
This dissertation is organized into 4 chapters; a general introduction, two papers pre­
pared for submission, and a general discussion. Each chapter has individual references and 
figures at the end. The papers are being submitted for publication to Nature and Brain Re­
search, respectively. The general discussion addresses the finding of both papers. 
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CHAPTER 2: G PROTEIN AND CAMP-DEPENDENT PROTEIN KINASE (PKA) 
MEDIATE AMYLOID B-PEPTIDE INHIBITION OF NEURONAL 
GLUCOSE UPTAKE 
A paper to be submitted to Nature 
Teerasak Prapong, Etsuro Uemura, and Walter H. Hsu 
Alzheimer's disease (AD) is characterized by deposition of amyloid B-peptide (AB), a 
39-43 amino acid protein ^. AJ3 has been shown to impair glucose uptake in cultured hippocam-
pal neurons^ and astrocytes^. It is not known whether AB affects neuronal glucose uptake in the 
brains of AD patients; however, ample evidence exists to suggest that glucose metabolism has 
changed in their brains'^ ^ ^. The mechanism by which AB inhibits glucose uptake in cultured 
cells is not known. Here we demonstrated a signaling pathway in which A625-35, a neurotoxic 
portion of the AB peptide corresponding to amino acids 25-35^^, inhibits neuronal glucose 
uptake by hippocampal neurons. The GP antagonist-2'^, which blocks Gs, prevented the in­
hibitory effect of AB on the glucose uptake. Cholera toxin, which stimulates adenylyl cyclase 
by activating Gs protein, also inhibited neuronal glucose uptake. Furthermore, the inhibitory 
effect of cholera toxin on glucose uptake was potentiated by AB. Exposure of cells to AB re­
sulted in a transitory increase in intracellular levels of cAMP. Addition of dibutyryl cAMP 
(Bt^cAMP) or an adenylyl cyclase activator, forskolin, to the culture medium inhibited neu­
ronal glucose uptake, and PKA inhibitor KT-5720 blocked the AB-mediated inhibition of glu­
cose uptake. Thus, our findings suggest that AB inhibits glucose uptake by activating the Gs-
coupled receptors and involves the cAMP-PKA system. 
To examine whether AB inhibition of neuronal glucose uptake is mediated by a G pro­
tein, hippocampal neurons were exposed to GP antagonist-2, which blocks the receptor-Gs 
interactionIn this study, cultured hippocampal neurons at day 4 post-plating were exposed 
to synthetic AB25-35 for 24 hr with or without 10 pM GP antagonist-2 in the culture medium. 
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The neuronal glucose uptake was measured and expressed as picomol ['"HZ] D-glucose per mg 
of cellular protein^. AB25-35 significantly inhibited neuronal glucose uptake [F(3,8)=66.8. 
p=0.0001] (Fig. la). Those neurons exposed to AB25-35 showed 40% less glucose uptake com­
pared with the control. However, the G protein antagonist prevented this inhibitory effect of 
Afi, suggesting G protein mediates AB inhibition of neuronal glucose uptake. 
To further assess the role of Gs on the inhibitory effect of A6 on neuronal glucose 
uptake, the effect of cholera toxin, which stimulates adenylyl cyclase by activating Gsl"^. was 
studied in cultured hippocampal neurons. In this study, neuronal glucose uptake was assessed at 
day 4 post-plating following exposure to cholera toxin (0.01,0.1 or 1 jig/ml) in the medium for 
one hr. Cholera toxin at 0.01 and 0.1 )ig/ml had no effect on neuronal glucose uptake, but 1 (ig/ 
ml cholera toxin significantly inhibited glucose uptake [F(3,8)=38.63, p=0.001] (Fig. lb). Based 
on this observation, the two low doses of cholera toxin (0.01, 0.1 jig/ml) were used to study 
whether this toxin potentiates the inhibitory effect of A6. In this study, neurons at day 4 post-
plating were exposed for 24 hr to both A625-35 coated on cover slips and cholera toxin at either 
0.01 or 0.1 ^.g/ml in the culture medium. Those neurons exposed to AB25-35 showed 38% less 
glucose uptake than the control (t=3.78. p=0.(X)01). When neurons were exposed to both A625-
35 and 0.1 |ig/ml cholera toxin, their glucose uptake was 53% less than the control (t=5.99, 
p=0.001) and 26% less than those exposed to AB25-35 alone (t=4.87, p=0.0004). Thus, cholera 
toxin potentiated the effect of AB25-35, suggesting that AB inhibits glucose uptake by activat­
ing the Gs-coupled receptors. 
Since Gs activates adenylyl cyclase ^  we studied the effect of AB on intracellular cAMP 
levels in cultured hippocampal neurons. In this smdy, neurons at day 4 post-plating were ex­
posed to AB25-35 for 2 hr, 2 days, or 3 days. Neurons were analyzed for cAMP content using 
radioimmunoassay (Amersham). A significant change in intracellular cAMP levels was ob­
served in neurons exposed to AB [F(1.12)=75.5, p=0.0001] and this change was time-depen­
dent [F(2.12)=19.3, p=0.0002] (Fig. 2a). The highest cAMP level was found in neurons ex­
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posed to A6 for 2 hr. followed by those neurons exposed to A6 for 48 hr. cAMP levels at 72 hr 
post-exposure were not different from the control. 
An elevation of intracellular cAMP levels by AB25-35 within 2 hr of application sug­
gests that A6 stimulates Gs-adenylyl cyclase coupling. To further assess the role of cAMP in 
neuronal glucose uptake, we studied the effect of c AMP on neuronal glucose uptake in hippoc-
ampal neurons. At post-plating day 4. cultured neurons were exposed for one hr to either Bt^c AMP 
(0,0.5. 1.5, 10.50 |iM) or forskolin (0. 10.25.50. 100 |iM). Neurons were assessed for glucose 
uptake and cellular protein at 0 and 1 hr post-treatment. Neuronal glucose uptake was signifi­
cantly inhibited by Bt,cAMP [F(5. 18)=9.07. p=0.0002] (Fig. 2b) or forskolin [F(4, 15)=4.68. 
p=0.0006] (Fig. 2c). This inhibitory effect was dose-dependent for both Bt^cAMP (r^.54) and 
forskolin (r^.58). Neurons exposed to either 50 jiM Bt,cAMP or 100 [iM forskolin showed 
only 13% of glucose uptake by the control neurons. Since A6 elevated intracellular cAMP 
levels within 2 hr, we assessed the inhibitory effect of A6 on glucose uptake following exposure 
for 3 hr to A625-35. Glucose uptake was significantly inhibited by A1325-35 (t=2.97. p=0.025) 
(Fig. 2d), suggesting an acute inhibitory effect of A625-35. 
Inhibition of neuronal glucose uptake by Bt^cAMP and forskolin suggests that glucose 
uptake is regulated by cAMP-dependent protein kinase (PKA). To examine whether PKA plays 
a regulatory role in neuronal glucose uptake, the effect of a PKA inhibitor KT-5720 was studied 
in cultured hippocampal neurons. At day 4 post-plating, neurons were exposed to KT-5720 (0.1 
|iM and 1 |iM) in the culture medium and AB25-35 on cover slips for 24 hr. Neuronal glucose 
uptake and cellular protein were assessed at 1 hr post-sampling time. Glucose uptake by control 
neurons was 40 pmol/mg cellular protein (Fig. 3). In contrast, AB25-35 significantly reduced 
glucose uptake to 15 pmol/mg cellular protein, i.e., 38% of the control neurons. This inhibitory 
effect of A625-35 was prevented by I |iM KT-5720, but not by 0.1 pM KT-5720. This dose-
dependent effect of the PKA inhibitor was highly significant [F(3, 16)=8.62, p=0012]. The 
result suggests an inhibitory role by PKA on neuronal glucose uptake. 
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Discussion 
The present study demonstrates that G protein and cAMP mediate A625-35 inhibition 
of neuronal glucose uptake. How these in vitro data relate to the decreased glucose metabolism 
in AD is not certain. It is possible that the decreased cerebral glucose uptake shown in AD may 
reflect, in part, the inhibitory effect of AB on neuronal and astrocytic glucose uptake. Such an 
hypothesis infers the presence of functional G protein-stimulated activity of adenylyl cyclase 
and cAMP in AD patients. Postmortem smdies of AD patients have shown normal G-protein 
levels catalytic activity of cAMP. and PKA^^"~ However, the regulatory function 
of G-protein on adenylyl cyclase was reported as either normal or reducedThis 
inconsistency may reflect differences in postmortem instability of the enzyme at different stages 
of Alzheimer's disease The regulatory function of G-protein on adenylyl cyclase could also 
be affected only at the terminal stage of AD disease. In this respect, our study seems to suggest 
that chronic exposure to AC desensitizes Gs in regulating adenylyl cyclase. AB inhibition of 
neuronal glucose uptake could also be mediated by Ca'Vcalmodulin-sensitive adenylyl cyclase 
and an increase cAMP levels, the process known to occur in the hippocampus^'^. However, 
Ca'Vcalmodulin-mediated inhibition of glucose uptake is less likely because it was shown that 
AB-induced apoptosis was not inhibited by KN-62. an inhibitor of Ca-Vcalmodulin dependent 
protein kinase^S. in neurons, the rate of glucose uptake depends on the number of GLUT3 on 
the plasma membrane, not on extracellular glucose concentration^^. In cultured hippocampal 
neurons, AB did not affect GLUTS protein levels, even after 6 hr of AB treatment^. This sug­
gests that AB induces an intrinsic functional change in GLUTS on the plasma membrane. In 
adipocytes, phosphorylation of GLUT4 is known to inhibit insulin-stimulated glucose trans­
port 27,28 In our smdy, the PKA inhibitor, KT-5720, prevented the inhibitory effect of AB on 
neuronal glucose uptake, suggesting GLUTS phosphorylation by PKA as an important regula­
tor of GLUTS function in hippocampal neurons. Also consistent with our present findings, the 
27 
PKA inhibitor, H-89, was shown to prevent AB-induced apoptosis^^. Considering the impor­
tance of glucose in the CNS function, the effect of A6 on neuronal glucose metabolism in AD 
warrents further study. 
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Figure legends 
Figure 1. G protein mediates A6 inhibition of neuronal glucose uptake. Abbreviations used for 
figure: C=control, AB=amyloid B-peptide, Ga=GP antagonist 2, Ctxl=l |ig/ml cholera toxin, 
Ctx. 1 =0.1 [ig/ml cholera toxin, Ctx.01 =0.01 |ig/ml cholera toxin, a, Culmred hippocampal neu­
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rons at day 4 post-plating were exposed to synthetic AB25-35 for 24 hr with or without 10 pM 
GP antagonist-2 in the culture medium. Those neurons exposed to Afi25-35 showed 40% less 
glucose uptake compared with the control. However. GP antagonist 2 prevented this inhibitory 
effect of A6. b. Neuronal glucose uptake was assessed at day 4 post-plating following exposure 
to cholera toxin (0.01, 0.1 or 1 Hg/ml) in the medium for one hr. Cholera toxin at 0.01 and 0.1 
(ig/ml had no effect on neuronal glucose uptake, but 1 p.g/ml cholera toxin significantly inhib­
ited glucose uptake, c. Two low doses of cholera toxin (0.01, O.I |a.g/ml) were used to study 
whether cholera toxin potentiates the inhibitory effect of A6 in neuronal glucose uptake. Neu­
rons at day 4 post-plating were exposed to synthetic AB25-35 for 24 hr with cholera toxin at 
either 0.01 or 0.1 p.g/ml in the culture medium. As noted above (a), neurons exposed to A625-
35 showed 38% less glucose uptake than the control. Neurons exposed to both AB25-35 and 
0.01 M.g/ml cholera toxin did not differ in their glucose uptake from those exposed to A625-35 
alone. However, those neurons exposed to both A625-35 and 0.1 |J.g/ml cholera toxin showed 
26% less glucose uptake than those exposed to AB25-35 alone. 
METHODS. A625-35 and scrambled control peptide were prepared according to Parpura-
Gill et al.^. Hippocampal neurons from 17E Sprague-Dawley rats were cultured according to 
Abe and Kimura^O; however, we used N2 instead of N1 supplement in our cultures. Neurons 
plated onto 24-well tissue culture plates were exposed to A625-35 or scrambled control peptide 
by using cover slips coated with the peptides. The coated-side was placed on top of the cultured 
neurons at post-plating day 4. Neuronal uptake of glucose was assayed by using ['•'C]D-glucose 
(313 |xCi/mmol, ICN) at final glucose concentrations of 600 nM (0.1 (iCi/500(il media in well). 
Cell lysates were used for determination of radioactivity by using a beta liquid scintillation 
counter (Packard, 1600TR) and for assay of total cell protein (Bio-Rad protein assay kit). Neu­
ronal uptake of ['•'C]D-glucose was expressed as pmol of glucose/mg of cellular protein. Each 
experiment was replicated three times (n=3) with 4 wells per condition per replication. All data 
were analyzed using all pups from each pregnant rat as an experimental unit. Data were ana­
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lyzed for treatment differences by analysis of variance and intertreatment differences were 
determined by post-hoc test (Tukey's). 
Figure 2. cAMP mediates AB inhibition of neuronal glucose uptake. Abbreviations used 
for figure: C=control. A6=amyloid B-peptide. a. Neurons at day 4 post-plating were analyzed 
for cAMP content following exposure to AB25-35 or scrambled control peptide for 2 hr. 2 days, 
or 3 days. A significant change in intracellular c AMP levels was observed in neurons exposed 
to AB and this change was time-dependent. The highest cAMP level was found in neurons 
exposed to AB for 2 hr. The cAMP level had fallen to the control level by 72 hr. b-c. Neurons at 
day 4 post-plating were assessed for glucose uptake and cellular protein at 0 and 1 hr following 
exposure for one hr to either Bt,cAMP (0. 0.5, 1. 5. 10, 50 |jM) or forskolin (0. 10, 25. 50, 100 
^iM). Neuronal glucose uptake was significantly inhibited by Bt., cAMP (b) or forskolin (c). 
This inhibitory effect was dose-dependent for both Bt, cAMP and forskolin. d. Since 6A25-35 
elevated cAMP by 2 hr (a), neurons at day 4 post-plating were assessed for glucose uptake at 0 
and 1 hr following exposure to either AB25-35 or forskolin (10 (iM) for 3 hr. Glucose uptake 
was significantly inhibited by AB25-35, suggesting an acute inhibitory effect of AB25-35. 
METHODS. The cAMP content of culmred neurons was determined with the acetyla-
tion protocol of '^I cAMP radioimmunoassay (Amersham). Each experiment was replicated 
three times (n=3) with 4 wells per condition per replication. All data were analyzed using all 
pups from each pregnant rat as an experimental unit. Data were analyzed for treatment differ­
ences by analysis of variance and intertreatment differences were determined by subsequent 
post-hoc test (Tukey's). 
Figure 3. PKA mediates AB inhibition of neuronal glucose uptake. Abbreviations used 
for figure: C=control, A6=amyloid B-peptide, PKAi=PKA inhibitor. Neurons at day 4 post-
plating were analyzed for glucose uptake and cellular protein following exposure to KT-5720 
(0.1 [iM or 1 |JM) in the culture medium and A625-35 or scrambled control peptide on cover 
slips for 24 hr. Glucose uptake by control neurons was 40 pmol/mg cellular protein. In contrast. 
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AB25-35 significantly reduced glucose uptake to 15 pmol/mg cellular protein, i.e., 38% of the 
control neurons. This inhibitory effect of AB25-35 was prevented by 1 |iM KT-5720, but not by 
0.1 pM KT-5720. This dose-dependent effect of PKA was highly significant. Each experiment 
was replicated three times (n=3) with 4 wells per condition per replication. All data were ana­
lyzed using all pups from each pregnant rat as an experimental unit. Data were analyzed for 
treatment differences by analysis of variance and intertreatment differences were determined 
by post-hoc test (Tukey's). 
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CHAPTER 3: EFFECTS OF INSULIN AND INSULIN-LIKE GROWTH FACTOR 1 
aCF-I) ON AB INHIBITION OF NEURONAL GLUCOSE UPTAKE 
A paper to be submitted to Brain Research 
Teerasak F*rapong, Etsuro Uemura, and Walter H. Hsu. 
Abstract 
Alzheimer's disease (AD) is characterized by deposition of amyloid B-peptide (AB). AB 
has been shown to impair glucose uptake in cultured hippocampal neurons in vitro. However, 
how AB inhibits glucose uptake is not known. We examined the effects of insulin and insulin­
like growth factor 1 (IGF-I) on the inhibitory effect of AB on neuronal glucose uptake. Insulin 
and IGF-I elevated neuronal glucose uptake, but the effect of IGF-I was more potent than insu­
lin. Neurons exposed to AB25-35 showed 38% less glucose uptake than the control. However, 
IGF-I and insulin prevented this inhibitory effect of AB. To study the signaling pathway of IGF-
I that stimulates glucose uptake, hippocampal neurons were studied for their glucose uptake 
following exposure to a phosphoinositide 3-kinase (PI3K) inhibitor (LY294C)02) or a mitogen-
stimulated protein kinase (MAPK) inhibitor (PD-98059). The stimulatory effect of IGF-I on 
neuronal glucose uptake was significantly inhibited by LY294002, but not by PD98059. The 
results suggest that (1) both IGF-I and insulin are effective in elevating neuronal glucose uptake 
and preventing the inhibitory effect of AB and (2) PI3K, but not MAPK, plays a regulatory role 
in neuronal glucose uptake. 
Introduction 
The neuropathology of AD is characterized by deposition of AB, a 39-43 amino acid 
protein [61]. AB is the primary protein component of neuritic plaques [38], the morphology of 
which varies from diffuse deposits of nonfibrillar AB to fibrillar AB. Although there are numer­
ous reports linking AB to neurotoxicity in vitro and in vivo [39], the mechanisms involved in 
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A6-mediated neuronal degeneration are not well understood. In vitro study has shown that A6 
impairs glucose uptake in cultured hippocampal neurons [37] and astrocytes [43]; however, it is 
not known whether AB affects neuronal and astrocytic glucose uptake in AD patients. There is 
some evidence suggesting that glucose metabolism is changed in the brains of AD patients 
[14,29,46,48]. It was calculated that reduction of cerebral glucose utilization ranges from 19% 
in mild cases to 40% and more in severely diseased patients [27,34], Alzheimer's patients have 
abnormally low blood glucose [28] and glucose has been shown to enhance memory in 
Alzheimer's patients and normal elderly adults [8.32]. Because glucose infusion is usually 
associated with elevation of plasma insulin, a group of Alzheimer's patients was further as­
sessed by raising plasma insulin, but preventing a rise in plasma glucose [9]. There was a 
striking memory enhancement in these patients, suggesting a functional importance of insulin 
in the brain. Reduced cerebral glucose uptake by individuals genetically at risk for developing 
AD also supports the notion that glucose deprivation precedes neuronal degeneration [31,45,47]. 
Neurons exposed to AI3 become more susceptible to glucose deprivation [7]; however. 
IGF-I and IGF analogues are effective in promoting cell survival under this condition [6,22]. 
Furthermore, IGF-I is shown to protect, and more importantly, to rescue rat hippocampal neu­
rons against A6-induced toxicity [ 13]. The protective mechanism of IGF-I is not known, but it 
was shown that insulin and IGF-I act as a neuronal growth factor [53,57]. In transgenic mice 
that overexpress IGF-I in the brain, glucose uptake increases significantly in the brain [20]. In 
vitro studies have also shown that IGF-I increases glucose uptake in skeletal muscle, mesangial 
cells, L6 myotubes, and PC 12 cells [17,23,35,60]. .Although several smdies in humans suggest 
the importance of insulin in hippocampal energy metabolism [19,26] £uid memory facilitation 
[8,9], it is not known whether insulin and IGF-I promote glucose uptake by neurons. In the 
present study, the effects of insulin and IGF-I on glucose uptake were examined in hippocam­
pal neurons exposed to AB25-35 in vitro. The signaling pathways of insulin and IGF-I that 
stimulate neuronal glucose uptake were examined by exposing hippocampal neurons to a 
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phosphoinositide S-kinase (PI3K) inhibitor or a mitogen-stimulated protein kinase (MAPK) 
inhibitor. 
Material and Methods 
A625-35, a neurotoxic portion of AB peptide that corresponds to amino acids 23-35 of 
A6 found in AD [61 ] and scrambled peptide [40]were synthesized and purified at the Univer­
sity of Iowa Protein Facility. The scrambled peptide has the following sequence: H-IIe-Met-
Leu-Gly-Asn-Gly-Ala-Ser-IIe-Gly-OH. Scrambled peptide and A625-35 were dissolved in 
Millipore-filtered double distilled water (pH 7.2, 10 mg/ml) and aliquots were stored at -20 °C. 
The working concentrations of each peptide (10-100 fXg/ml) were prepared by further dilution 
in double-processed tissue culture water. Rat hippocampal neurons were prepared by modify­
ing the method previously described by [ 1 ]; however, we used N2 instead of NI supplement in 
our culture. E17 - E18 pregnant rats (Holtzman) were euthanized in the halothane chamber. 
The fetuses were removed by cesarean section. Then, the brains were dissected and put into 
cold Earles Balance Salt Solution (EBSS) by sterile technique. Hippocampi were dissected 
under the stereoscope and placed into cold sterile EBSS. The tissues were incubated in a 0.2% 
trypsin EBSS solution for 15 minutes and in a 0.2% trypsin inhibitor EBSS solution for 5 
minutes, respectively. The tissue was dissociated by tituration through a fire-polished pasteur 
pipette in Minimum Essential Medium (MEM) supplemented with 40 mM glucose, 2 mM L-
glutamine, 1 mM pyruvate, 2 mM NaHCO^, 100 lU/ml penicillin, 100 |ig/ml streptomycin and 
I ml of N-2 supplement (Gibco). Tissue suspension with a density of 1-3 x lO' cells/mi in 
MEMN2 media was plated in 24 -well tissue culture plates coated with polyethylenelmine 
(PEI) alone or re-coated with either A625-35 or scrambled peptide. The culture was incubated 
at 37 °C in 5% CO, humidified atmosphere for 4 days before treatment. 
To study the effect of AB, IGF-I, and insulin on neuronal glucose uptake, cells were 
exposed, at day 4 post-plating, to 10 nM AB25-35 coated on cover slips, 50 nM IGF-I, or 50 nM 
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insulin for 24 hr. Cover slips coated with AB25-35 were prepared by allowing 50 |il of AB25-35 
placed on a round cover slip (12 mm in diameter) to air dry. The coated-side of the cover slip 
was placed on top of cultured neurons. Neuronal uptake of glucose was assayed by using D-[U-
'•'Cjglucose (313 mCi/mmol, ICN) at final glucose concentration of 600 nM (0.1 |iCi/500 p.1 
media in well). Cell lysates were used for determination of radioactivity by using a beta liquid 
scintillation counter (Packard. 1600TR) and for assaying of total cell protein (Bio-Rad protein 
assay kit). Neuronal uptake of ['"'C] D-glucose was expressed as pmols of glucose/mg of cellu­
lar protein. To examine the signaling pathway of IGF-I that elevates neuronal glucose uptake, 
hippocampal neurons at day 4 post-plating were exposed to 50 nM IGF-I or 50 nM insulin for 
24 hr, in the presence of either 50 |iM PI3K inhibitor (LY294002, Eli Lilly) or 30pM MAPK 
inhibitor (PD-98059. Biomol). Each experiment was replicated three times (n=3) with 4 wells 
per condition per replication. All data were analyzed using all pups from each pregnant rat as an 
experimental unit. Data were analyzed for treatment differences by analysis of variance and 
intertreatment differences were determined by subsequent post-hoc test (Tukey's ). 
Results 
The effects of insulin and IGF-I on glucose uptake were examined in hippocampal neu­
rons exposed to AB25-35. Hippocampal neurons responded significantly to Afi25-35. IGF-I. 
and insulin [F(5,12)=72.9, p=0.000I] (Fig. 1). Neuronal glucose uptake was increased by either 
IGF-I (t=-6.78, p=0.0001) or insulin (t=-3.29, p=0.006), but the effect of IGF-I was more potent 
than insulin (t=3.49. p=0.0045). AB25-35 inhibited the glucose uptake by 38% compared with 
the control (t= 10.84, p=0.0001). Both IGF-I and insulin prevented this inhibitory effect of AI325-
35, but the preventive effect of IGF-I was more potent than that of insulin (t=3.47, p=0.0046). 
Thus, neurons exposed to both AB and IGF-I showed significantly more glucose uptake than 
the control (t=-2.81, p=0.016), while those cells exposed to both AB and insulin had glucose 
uptake similar to the control. The results suggest that both IGF-I and insulin are effective in 
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elevating neuronal glucose uptake and preventing an inhibitory effect of A6. 
Since both IGF-I and insulin significantly elevated neuronal glucose uptake, the effects 
of a PI3K inhibitor (LY294002) and a MAPK inhibitor {PD-98059) were assessed on the stimu­
latory effect of IGF-I on glucose uptake. The effect of 50 pM LY294002 on glucose uptake is 
shown in Fig. 2. PI3K inhibitor alone had no effect on neuronal glucose uptake; however, it 
significantly prevented the stimulatory effect of IGF-I on glucose uptake (t=2.85, p=0.02). The 
effect of PD-98059 is shown in Fig. 3. The MAPK inhibitor alone did not affect neuronal 
glucose uptake; however, unlike the PI3K inhibitor, the MAPK inhibitor did not prevent the 
stimulatory effect of IGF-I on glucose uptake. The results suggest that PI3K. not MAPK. medi­
ates the elevation of glucose uptake by IGF-I. 
Discussion 
The present study has shown that both IGF-I and insulin are effective in elevating glu­
cose uptake by cultured hippocampal neurons. In both skeletal muscle and adipocytes, insulin 
and IGF-I were shown to control the actual number of GLUT4 in the plasma membrane by 
stimulating translocation of GLUT4 [36.44.59]. Similarly, insulin and IGF-I were shown to 
translocate GLLrT3 in L6 myotubes [41]; however, what regulates translocation of neuronal 
GLUT3 is not known at present. Insulin and IGF-I share structural and functional feamres, 
including an a-subunit that binds the hormone-like agent and a B-subunit that has a tyrosine-
specific protein kinase [56]. The metabolic effects of these hormones are initiated by their 
binding to the extracellular domain of the specific membrane receptors, which lead to the acti­
vation of, among others, Ras and PI3K [21,54]. Many of these kinases appear to be arranged in 
cascades, including a cascade that results in the elevation of glucose uptake in insulin sensitive 
cells [55]. The signaling pathways that stimulate neuronal glucose uptake are not known. In 
adipocytes, PI3K was shown to increase GLIJT4 translocation to the plasma membrane and 
glucose transport [16,24,30,33]. Furthermore, a PI3K inhibitor, LY294002, was shown to in­
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hibit glucose uptake [50] by interfering with insulin mediated translocation of GLUT4 [5]. 
Similarly, our smdy demonstrated that LY294002, but not MAPK inhibitor, inhibits IGF-I stimu­
lated neuronal glucose uptake. This suggests that IGF-I stimulated increase in glucose transport 
by hippocampal neurons involves a signaling pathway of PI3K. 
Those neurons exposed to AB25-35 for 24 hr showed 38% less glucose uptake com­
pared with the control. Thus, our data confirms the previous study [37)]. The present study has 
also shown that insulin and IGF-I prevent this inhibitory effect of A6, elevating the glucose 
uptake either to the control levels by insulin or more than control levels by IGF-I. In healthy, 
nonstarved mammalian brain, glucose is the only substrate for the formation of energy in the 
form of ATP [15]. Neurons with impaired glucose uptake or exposed to AB have impaired 
mitochondrial activity and suppressed production of ATP [39]. How these in vitro data relate to 
the brains of AD patients is not certain, but it was estimated, based on the rates of oxidized 
glucose and oxygen consumption, that the rate of cerebral ATP formation decreases by 7% in 
early-onset AD and 20% in late-onset AD [25]. Thus, the capacity of insulin and IGF-I to 
promote glucose uptake and prevent AB inhibition of neuronal glucose uptake is of importance 
to normal and pathological brain functioning. An increasing body of evidence suggests that 
insulin has a vital role in brain function [58]. Expression of the insulin gene and insulin synthe­
sis occur in a highly specific pattern, with the highest density in hippocampal pyramidal neu­
rons [12]. Plasma insulin was also shown to cross the blood-brain barrier by saturable receptor-
mediated transcytosis, and residual insulin is removed through the CSF [2,3,52]. At present, 
normal insulin and IGF-I levels in the human brain are not known. However, a deficit in these 
hormones is suspected in the brains of AD patients because of their higher plasma insulin and 
IGF-I, and lower CSF insulin levels [10]. Insulin and IGF-I receptors are also present in the 
human brain [42,49,51 ], and their numbers increase in the brains of AD patients [4,11,18]. If 
this proliferation of insulin and IGF-I receptors is the brain's attempt to compensate for a lack 
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of insulin and IGF-I, the reduced cerebral glucose utilization found in AD may reflect the cere­
bral insulin and IGF-I deficit in AD [27]. 
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Control IGF-I Insulin A6+IGF-I AB+Insulin 
Experimental Condition 
Figure 1. The effects of insulin and IGF-I on glucose uptake in hippocampal neurons exposed 
to AB25-35. 
50 
50 
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Experimental Condition 
Figure 2. The effect of a PI3K inhibitor (LY294002) on the stimulatory effect of IGF-I on 
neuronal glucose uptake. 
51 
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Figure 3. The effect of a MAPK inhibitor (PD-98059) on stimulatory effect of IGF-I on 
neuronzd glucose uptake. 
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CHAPTER 4: GENERAL DISCUSSION 
The research in this dissertation was to test the hypothesis that (I) G protein and c AMP 
mediate Afi inhibition of neuronal glucose uptake, (2) Insulin and IGF-I prevent the inhibitory 
effect of Afi on neuronal glucose uptake, and (3) either IP3K or MAPK mediates the effect of 
IGF-I (Figure 1). The results from the studies suggested that (1) the inhibitory effect of Afi 
(A625-35) on glucose uptake by culture hippocampal neurons is mediated via a G protein and 
cAMP-dependent PKA pathway, (2) both insulin and IGF-I induce elevation of glucose uptake 
and prevent the inhibitory effect of Afi, and (3) IGF-I stimulates glucose uptake via IP3-Kinase. 
To test the first hypothesis, G Protein antagonist-2 (GPAnt-2) was used to block the 
binding of the receptor with G protein [44]. The GPAnt-2 minimized the inhibitory effect of 
AB25-35 on neuronal glucose uptake, suggesting that G protein plays a key role in A6 decreas­
ing glucose transport of neurons. It is known that cholera toxin activates G protein activity 
resulting in more cAMP in the cells [30]. Cholera toxin in the present study not only inhibited 
neuronal glucose uptake, but also potentiated the inhibitory effect of Afi. Based on these data, 
cAMP and PKA were speculated as two molecules involved in the pathway. By using dibutyryl 
cAMP (Bt^cAMP) and forskolin. it was concluded that they have an inhibitory role in neuronal 
glucose uptake further supporting the involvement of cAMP. In the cAMP-dependent protein 
kinase pathway, cAMP exerts its action on cAMP-dependent protein kinase or PKA [45]. The 
present study shows that PKA inhibitor can prevent the inhibitory effect of Afi on neuronal 
glucose uptake. This could be the reason for the attenuation effect of PKA on Afi toxicity on 
cultured rat cerebral neurons shown by Ueda et al. [59]. 
The present study demonstrates that G protein and cAMP mediate Afi25-35 inhibition 
of neuronal glucose uptake. How these in vitro data relate to the decreased glucose metabolism 
in AD is not certain. It is possible that the decreased cerebral glucose uptake shown in AD may 
reflect, in part, the inhibitory effect of Afi on neuronal and astrocytic glucose uptake. Such an 
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Figure 1. Hypothetical pathways mediating the inhibitory effcct of A6 and the stimula­
tory effect of insulin and IGF-I on neuronal glucose uptake 
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hypothesis infers the presence of functional G protein-stimulated activity of adenylyl cyclase 
and cAMP in AD patients. Studies from brain tissues of AD patients revealed that Ga-subunit 
is unchanged [42] or even elevated Gs a-mRNA [26]. Catalytic activity of cAMP and cAMP-
dependent protein kinase was also reported as normal [9,22,43,49]. Nevertheless, other studies 
indicated the opposite [16,53]. This inconsistency may reflect differences in postmortem insta­
bility of the enzyme at different stages of Alzheimer's disease [9]. 
The present study assessed intracellular cAMP following exposure to A625-35 for 2 
hrs to 72 hrs. Interestingly, chronic exposure to A6 resulted in a decrease of cAMP that may be 
due to desensitization of G protein-coupled receptors. The mechanism of desensitization of G 
protein-coupled receptors was reviewed; it was found that tachykinin, M2 muscarinic and nico­
tinic receptors can be desensitized [15]. The tachykinin receptor was reported to be a site for AB 
binding [14,66]. More over, nicotinic receptors and M2 muscarinic receptors are decreased in 
AD patients [41,54]. Both cAMP and PKA also play a role in the process of desensitization 
[15]. It was proposed here that in the early state of decreasing glucose uptake caused by AB, 
cAMP and PKA might be key molecules affecting the intrinsic activity of GLUT3. Conse­
quently, rising cAMP and PKA activity leads to desensitization of receptors for AB binding 
which would lead to a decline of cAMP. The present study showed that the cAMP level is 
inversely related to the rate of glucose uptake. Decreased cAMP levels as a result of desensiti­
zation of G protein-coupled receptors should make the rate of glucose uptake return to normal. 
However, it did not. It is possible that AB-mediated elevation of cAMP suppressed GLUT3 
mRNA, and the subsequent decrease in number of GLUT3 available for glucose transport. In 
3T3-L1 adipocytes, increasing cAMP by either forskolin or 8-bromo-cAMP was shown to re­
press expression of the GLUT4 gene [32]. However, GLUT3 mRNA levels in neurons chroni­
cally exposed to AB is not known. 
The second study was to test the hypothesis that insulin and IGF-I prevent the inhibitory 
effect of AB on glucose uptake and either PI3K or MAPK mediates the effect of IGF-I. The 
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brains of humans and rodents were shown to have receptors, mRNAs and binding proteins for 
insulin and IGFs [ 1 -5,7,8.10,13,19,24.27,29,33.37-40,46.48,51,52,56-58,62,64,65]. Recent stud­
ies found alteration of insulin and its receptors in AD patients [23]. The patients have high 
levels of plasma insulin and IGF. whereas their CSF levels are lower than non AD people of the 
same age [18]. In addition, insulin and glucose were shown to improve memory in AD patients 
[17,35], and injecting streptozotocin into the rat brain was shown to impair memory due to 
desensitization of insulin receptors [31.47]. IGF-I. which has a structure and receptors similar 
to insulin was shown to prevent A6 toxicity and increase glucose uptake in PC 12 cells in vitro 
[20,65]. Whether and how insulin and IGF exert their function on neuronal glucose uptake in 
vivo is not known. 
The present study showed that both insulin and IGF-I elevate glucose uptake in the 
cultured neurons. The result agrees with the previous study in PC 12 cells [65]. IGF-I and IGF-
n were reported to have their protective action against calcium-mediated hypoglycemic dam­
age in cultured hippocampal and septal neurons [12]. However, the study did not look for the 
effect of IGFs on normal glucose uptake. The hippocampus is one of the prominent areas in the 
brain having IGF-I receptors [29]. This suggests why IGF-I has more potency to increase glu­
cose uptake in the cultures used in this study. Nevertheless, how insulin and IGFs regulate 
neuronal glucose uptake is not known. It was demonstrated in L6 myotubes that insulin and 
IGF-I increase translocation of GLUT3 from the cytosol pool to plasma membrane[6,63]. How­
ever, the translocation of GLUT3 in neurons has not been demonstrated at present. The present 
study showed that both IGF-I and insulin were able to prevent the inhibitory effect of AB25-25 
on glucose uptake, although IGF-I is more potent than insulin. Insulin was shown to increase 
GLUT3 mRNA in rat brain under chronic insulin hypoglycemia [60], suggesting the involve­
ment of insulin in cerebral glucose metabolism. 
The present study also investigated the pathway used by IGF-I to regulate neuronal 
glucose uptake. The results showed that a IP3K inhibitor (LY294002), but not MAPK inhibitor 
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(PD98059), prevents the stimulatory effect of IGF-I on neuronal glucose uptake. This suggests 
that IGF-I modulates the glucose uptake via a PI3K pathway. The metabolic effects of IGF-I 
and insulin are initiated by their binding to the extracellular domain of specific membrane 
receptors, which lead to the activation of, among others, Ras and PI3K [25,55], Many of these 
kinases appear to be arranged in cascades, including a cascade that results in the elevation of 
glucose uptake in insulin sensitive cells [61]. The signaling pathways that stimulate neuronal 
glucose uptake are not known. In adipocytes, PI3K was shown to increase GLUT4 transloca­
tion to the plasma membrane and glucose transport [21,28,34,36]. Furthermore, a PI3K inhibi­
tor, LY294002, was shown to inhibit glucose uptake [50] by interfering with insulin mediated 
translocation of GLUT4 [11]. Similarly, the present study demonstrated that LY294002, but 
not a MAPK inhibitor (PD98059), inhibits IGF-I stimulated neuronal glucose uptake. This 
suggests that IGF-I stimulated increase in glucose transport by hippocampal neurons involves a 
signaling pathway of PI3K. 
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